triazoles has been researched along with Cancer, Second Primary in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y | 1 |
| Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; van de Velde, CJH; van den Bosch, J; van Leeuwen-Stok, AE | 1 |
| An, HJ; Byun, JH; Chung, SM; Ha, KS; Hong, JH; Jung, SS; Jung, YH; Kang, D; Kim, JS; Lee, GJ; Park, IY; Park, JC; Park, S; Park, WC; Suh, YJ; Won, HS; Woo, IS | 1 |
| Bienkiewicz, A; Cialkowska-Rysz, A; Gora, E; Gottwald, L; Jesionek-Kupnicka, D; Korczynski, J; Morawiec, Z; Piekarski, JH; Sowa, P | 1 |
| Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V | 1 |
| Baron, M; d'Anjou, J; Dessogne, P | 1 |
| Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
| Perez, EA | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 1 |
1 review(s) available for triazoles and Cancer, Second Primary
| Article | Year |
|---|---|
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
5 trial(s) available for triazoles and Cancer, Second Primary
| Article | Year |
|---|---|
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2023 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2018 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Second Primary; New Zealand; Nitriles; North America; Postmenopause; Proportional Hazards Models; Receptors, Steroid; Risk Factors; Selective Estrogen Receptor Modulators; South Africa; South America; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Secondary Prevention; Survival Rate; Tamoxifen; Triazoles | 2005 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogens; Humans; Kaplan-Meier Estimate; Letrozole; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Patient Acceptance of Health Care; Placebos; Postmenopause; Progesterone; Proportional Hazards Models; Recurrence; Tamoxifen; Triazoles | 2008 |
6 other study(ies) available for triazoles and Cancer, Second Primary
| Article | Year |
|---|---|
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Female; Hormone Replacement Therapy; Humans; Letrozole; Male; Mastectomy; Middle Aged; Neoplasms, Second Primary; Nitriles; Prognosis; Receptor, ErbB-2; Republic of Korea; Tamoxifen; Trastuzumab; Treatment Outcome; Triazoles | 2016 |
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Stromal Tumors; Humans; Neoplasms, Second Primary; Nitriles; Rhabdomyosarcoma, Embryonal; Stomach; Triazoles; Uterine Neoplasms; Uterus | 2008 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; DNA; Female; Genotype; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Middle Aged; Neoplasms, Second Primary; Nitriles; Polymerase Chain Reaction; Prognosis; Triazoles | 2012 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinosarcoma; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Metrorrhagia; Middle Aged; Neoplasms, Second Primary; Nitriles; Risk; Tamoxifen; Triazoles; Uterine Neoplasms | 2004 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |